A Phase 4 interventional study of Trifarotene Cream and Trifarotene Vehicle Cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 25 sites in 2 countries. Open to participants aged 13 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-12-20.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 8th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 13 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2021.
This study's enrollment of 123 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 26th largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2021, is one of 20 in phase 4, and was the 48th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants
Key Inclusion Criteria:
Participant with clinical diagnosis of acne vulgaris, defined by:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Trifarotene Cream
Drug: Trifarotene Vehicle Cream
Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
Also known as: Aklief
Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24
The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.
Time frame: Baseline and Week 24
Percent Change From Baseline in PIH ODS Scores at Week 24
The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.
Time frame: Baseline and Week 24
Absolute Change From Baseline in PIH ODS Scores at Weeks 12, 16 and 20
The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.
Time frame: Baseline, at Week 12, Week 16 and Week 20
Percent Change From Baseline in PIH Overall Disease Severity Scores at Weeks 12, 16 and 20
The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.
Time frame: Baseline, at Week 12, Week 16 and Week 20
The study was conducted at 18 investigational centers in the United States and Spain from 22 Dec 2021 to 15 Dec 2022.
| Milestone | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Started | 60 | 63 |
| Completed | 45 | 53 |
| Not completed | 15 | 10 |
| Withdrew: Lost to follow-up | 9 | 7 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Non-compliance with investigational product | 1 | 1 |
| Withdrew: Withdrawal by parent or guardian | 2 | 1 |
The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.
| score on a scale | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24 | -2.1 ± 0.27 | -2.1 ± 0.24 |
The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.
| Percent change | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Percent Change From Baseline in PIH ODS Scores at Week 24 | -45.4 ± 5.73 | -44.9 ± 5.18 |
The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.
| score on a scale | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Absolute change at Week 12 | -1.6 ± 0.18 | -1.1 ± 0.17 |
| Absolute change at Week 16 | -1.9 ± 0.2 | -1.7 ± 0.19 |
| Absolute change at Week 20 | -2.0 ± 0.22 | -1.9 ± 0.21 |
The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.
| Percent change | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Percent Change at Week 12 | -34.4 ± 3.78 | -23.6 ± 3.60 |
| Percent Change at Week 16 | -41.2 ± 4.35 | -36.1 ± 4.17 |
| Percent Change at Week 20 | -43.9 ± 4.83 | -41.0 ± 4.75 |
Collected over Adverse events were assessed from screening up to Week 24. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trifarotene (CD5789) Cream | 0/60 (0%) | 0/60 (0%) | 10/60 (16.7%) |
| Trifarotene Vehicle Cream | 0/63 (0%) | 1/63 (1.6%) | 19/63 (30.2%) |
| Event | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Bipolar DisorderPsychiatric disorders | 0/60 | 1/63 |
| Event | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream |
|---|---|---|
| COVID-19Infections and infestations | 3/60 | 6/63 |
| InfluenzaInfections and infestations | 2/60 | 1/63 |
| NasopharyngitisInfections and infestations | 2/60 | 1/63 |
| HeadachedNervous system disorders | 0/60 | 2/63 |
| DysmenorrhoeaReproductive system and breast disorders | 0/60 | 2/63 |
| VomitingGastrointestinal disorders | 1/60 | 0/63 |
| Attention deficit hyperactivity disorderPsychiatric disorders | 1/60 | 0/63 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/60 | 1/63 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/60 | 0/63 |
| Bacterial vaginosisInfections and infestations | 0/60 | 1/63 |
| Age, Continuous(years) | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream | Total |
|---|---|---|---|
| Mean | 22.7 ± 6.30 | 21.9 ± 5.95 | 22.3 ± 6.11 |
| Sex: Female, Male(Participants) | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream | Total |
|---|---|---|---|
| Female | 45 | 48 | 93 |
| Male | 15 | 15 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 27 | 48 |
| Not Hispanic or Latino | 39 | 36 | 75 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Trifarotene (CD5789) Cream | Trifarotene Vehicle Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 11 | 6 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 22 | 23 | 45 |
| White | 25 | 31 | 56 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2021 to primary completion in Dec 2022, 11 months.
Results were first posted in Dec 2023, 1 year after primary completion.
Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 11 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene